Contineum Therapeutics (CTNM) Return on Capital Employed (2024 - 2026)
Contineum Therapeutics (CTNM) recorded quarterly Return on Capital Employed of 25.48% in Q1 2026, up 16.13% quarter-over-quarter from 30.38% in Q4 2025, and up 456.0% on a YoY basis from 4.58% in Q1 2025.
Contineum Therapeutics (CTNM) Return on Capital Employed (2024 - 2026) Analysis & Trends
Contineum Therapeutics' Return on Capital Employed history runs 3 years deep, the most recent figure standing at 25.48% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 456.0% year-over-year to 25.48%; the TTM figure through Mar 2026 stood at 25.48% (up 456.0% YoY), while the FY2025 annual figure was 28.96%, up 252.0% from the prior year.
- Return on Capital Employed was 25.48% for Q1 2026 at Contineum Therapeutics, up from 30.38% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 0.06% in Q1 2024 to a low of 37.67% in Q3 2025.
- Historically, Return on Capital Employed has averaged 26.63% across 3 years, with a median of 29.52% in 2024.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed sank 3011 bps in 2025, then surged 456 bps in 2026.
- A 3-year view of Return on Capital Employed shows it stood at 24.89% in 2024, then slipped by 22 bps to 30.38% in 2025, then advanced by 16 bps to 25.48% in 2026.
- The last three Return on Capital Employed figures came in at 25.48% (Q1 2026), 30.38% (Q4 2025), and 37.67% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Contineum Therapeutics | 423.05 Mn | 423.05 Mn | - | -25.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.48% |
| Dec 31, 2025 | -30.38% |
| Sep 30, 2025 | -37.67% |
| Jun 30, 2025 | -36.01% |
| Mar 31, 2025 | -30.05% |
| Dec 31, 2024 | -24.89% |
| Sep 30, 2024 | -25.70% |
| Jun 30, 2024 | -29.52% |
| Mar 31, 2024 | 0.06% |